BCAR1 and breast cancer: These data suggest important therapeutic and translational value of p130Cas in ErbB2 breast cancer and supports the hypothesis that p130Cas/ErbB2 interaction can serve as a potential target for the discovery and development of new anticancer agents, that can be used in combination with standard therapy to manage and control Trastuzumab resistance.